CRESCENT BIOPHARMA, INC. (CBIO) Form 424B5 — Jul 14, 2026
Crescent Biopharma has filed a preliminary prospectus supplement for a public offering of ordinary shares and pre-funded warrants to fund the clinical development of its oncology candidates CR-001, CR-002, and CR-003, as well as general corporate purposes. Jefferies, TD Cowen, Guggenheim Securities, Cantor, and LifeSci Capital are acting as the joint book-running managers for the offering. The company estimates that its cash and cash equivalents were approximately $171.6 million as of June 30, 2026, and reported a last sale price of $15.69 per share on July 13, 2026.
Key figures
- Cash Position
- $171.6 million
- Last Sale Price
- $15.69
- Shares Outstanding
- 27,571,935
- Net Tangible Book Value
- $183.8 million
Price after filing
Close on the filing date to close N calendar days later (from $15.30). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.